Paraboschi, I;
Privitera, L;
Kramer-Marek, G;
Anderson, J;
Giuliani, S;
(2021)
Novel Treatments and Technologies Applied to the Cure of Neuroblastoma.
Children
, 8
(6)
, Article 482. 10.3390/children8060482.
Preview |
Text
Anderson_ Novel Treatments and Technologies Applied to the Cure of Neuroblastoma_VoR.pdf - Published Version Download (2MB) | Preview |
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumour in childhood, accounting for approximately 15% of all cancer-related deaths in the paediatric population1. It is characterised by heterogeneous clinical behaviour in neonates and often adverse outcomes in toddlers. The overall survival of children with high-risk disease is around 40–50% despite the aggressive treatment protocols consisting of intensive chemotherapy, surgery, radiation therapy and hematopoietic stem cell transplantation2,3. There is an ongoing research effort to increase NB’s cellular and molecular biology knowledge to translate essential findings into novel treatment strategies. This review aims to address new therapeutic modalities emerging from preclinical studies offering a unique translational opportunity for NB treatment.
| Type: | Article |
|---|---|
| Title: | Novel Treatments and Technologies Applied to the Cure of Neuroblastoma |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/children8060482 |
| Publisher version: | http://dx.doi.org/10.3390/children8060482 |
| Language: | English |
| Additional information: | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). |
| Keywords: | Neuroblastoma, Monoclonal Antibodies, Antibody-Drug Conjugates-Based Therapy, Third-Generation Tyrosine Kinase Inhibitor, Drug-Loaded Nanoparticles, cellular immunotherapies, tumour vaccines, radiation therapies, intra-operative treatments, ANTITUMOR-ACTIVITY, T-CELLS, AMINOPEPTIDASE-A, SURVIVAL, COMBINATION, EFFICACY, GROWTH, MODEL, RADIOTHERAPY, INHIBITION |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10129978 |
Archive Staff Only
 |
View Item |
